Articles

Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms

Mikhail Kostinov, Oksana Svitich, Alexander Chuchalin, Natalya Abramova, Valery Osiptsov, Ekaterina Khromova, Dmitry Pakhomov, Vitaly Tatevosov, Anna Vlasenko, Vilia Gainitdinova, Kirill Mashilov, Nadezhda Kryukova, Irina Baranova, Anton Kostinov

Article Type

Original Research

Published

This article aims to assess the secretion of SIgA in the nasal and pharyngeal compartments and saliva of patients with COVID-19 and to investigate the possibility and efficiency of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms.

Read more

The future of clinical trials and drug development: 2050

Timothy C Hardman, Rob Aitchison, Richard Scaife, Jean Edwards, Gill Slater, on behalf of the Committee of the Pharmaceutical Contract Management Group

Article Type

Commentary

Published

This article discusses a workshop held at the 18th Annual Conference of the Pharmaceutical Contract Management Group (PCMG) in Krakow on 9th September 2022, which asked over 200 delegates what the clinical trial landscape would look like in 2050.

Read more

A real-world evidence study evaluating consumer experience of Supradyn Recharge or Supradyn Magnesium and Potassium during demanding periods

Barbara Moroni, Veronika Óvári, Cristina Nicastro, Raffaella de Salvo, Andreas Ehret

Article Type

Original Research

Published

This article reports findings on consumption behaviour, reason for intake and frequency of intake as well as consumer experience, satisfaction and characteristics of Supradyn Recharge or Supradyn Magnesium+Potassium.

Read more

Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report

Ahmed Hashem

Article Type

Case Report

Published

This case report discusses daily treatment with silymarin and highlights moderate efficacy and a good safety profile in the management of non-alcoholic steatohepatitis (NASH) and liver function with no side-effects, supporting silymarin as a promising supplemental intervention that can normalize liver activity in non-alcoholic fatty liver disease and NASH.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.